Takeda officer plans sale of 116,191 shares

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD (TAK) received a notice that officer Andrew Stewart Plump, through the ANDREW S PLUMP 2020 REV TR U/A 12/2/20 and Fidelity Brokerage Services LLC as attorney-in-fact, intends under Rule 144 to sell up to 116,191 shares of Takeda common stock on the NYSE.

The notice also reports that during the prior three months, Plump sold 19,651 shares of Takeda common stock on August 19, 2026 for $363,348.49.

Key Figures

Proposed shares to be sold: 116,191 shares Recent shares sold: 19,651 shares Proceeds from recent sale: $363,348.49 +2 more

5 metrics

Proposed shares to be sold 116,191 shares Takeda common stock proposed for sale under Rule 144

Recent shares sold 19,651 shares Takeda common stock sold on August 19, 2026

Proceeds from recent sale $363,348.49 Total consideration for 19,651 shares sold on August 19, 2026

Trust reference date December 2, 2020 Date in the name ANDREW S PLUMP 2020 REV TR U/A 12/2/20

Notice date September 2, 2026 Date of the Form 144 notice for proposed Takeda share sales

Key Terms

Rule 144, RSU's and PSU's, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU's and PSU's financial

"Common | 08/20/2020 | RSU's and PSU's | Issuer"

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Andrew"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing disclose for TAKEDA PHARMACEUTICAL (TAK)?

It discloses that officer Andrew Stewart Plump, via a revocable trust and Fidelity Brokerage Services LLC as attorney-in-fact, plans under Rule 144 to sell up to 116,191 shares of Takeda common stock on the NYSE.

How many TAK shares are proposed to be sold under this Form 144?

The filing states a proposed sale of up to 116,191 shares of Takeda common stock. These shares are held in the ANDREW S PLUMP 2020 REV TR U/A 12/2/20 and are to be sold through Fidelity Brokerage Services LLC.

What prior sales of TAK stock are reported in the last three months?

The notice reports that on August 19, 2026, Andrew Stewart Plump sold 19,651 shares of Takeda common stock for total consideration of $363,348.49 during the preceding three-month period.

What is the relationship of the seller to Takeda Pharmaceutical (TAK)?

The person for whose account the securities are to be sold is Andrew Stewart Plump, identified in the filing as an Officer of Takeda Pharmaceutical Co Ltd.

How are the TAK shares to be sold held according to the Form 144?

The remarks state that the shares are being sold from the ANDREW S PLUMP 2020 REV TR U/A 12/2/20, with Fidelity Brokerage Services LLC acting as attorney-in-fact for Andrew Stewart Plump.

When was the Form 144 notice for TAK filed?

The Form 144 notice is dated September 2, 2026, covering the proposed sale of up to 116,191 Takeda common shares and reporting the earlier August 19, 2026 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:14 PM Accepted by SEC EDGAR 09/02/2026 - 04:14 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977689
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TAKEDA PHARMACEUTICAL CO LTD
SEC File Number	001-38757
Address of Issuer	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO JAPAN 103-8668
Phone	81332782111
Name of Person for Whose Account the Securities are To Be Sold	Plump Andrew Stewart
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	116191	2148372.09	1579836830	09/02/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2020	RSU's and PSU's	Issuer			116191	08/20/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Plump Andrew Stewart C/O TAKEDA PHARMACEUTICAL CO LTD 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU Tokyo M0 103-8668	Common Stock	08/19/2026	19651	363348.49

144: Remarks and Signature

Remarks	shares are being sold from ANDREW S PLUMP 2020 REV TR U/A 12/2/20
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Audrey Skillern as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Andrew Stewart Plump
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)